(Adds details)
Nov 24 (Reuters) - Biopharmaceutical company Allos Therapeutics said U.S. regulators have granted orphan drug status for its experimental drug to treat diffuse large b-cell lymphoma (DLBCL), a type of cancer.
Pralatrexate, which has already received FDA's orphan drug status to treat T-cell lymphoma, is being tested as a treatment for large B-cell lymphoma.
DLBCL is a cancer of the B-lymphocytes and represents 30 percent of non-Hodgkin's lymphomas in adults. There are 63,000 new cases in the United States diagnosed per year.
Orphan drug status is given to drugs that treat diseases affecting fewer than 200,000 people in the United States and grants drug developers seven years of market exclusivity.
Shares of the company closed at $6.50 Monday on Nasdaq.
(Reporting by Vidya L Nathan and Anand Basu in Bangalore; Editing by Jarshad Kakkrakandy) Keywords: ALLOSTHERAPEUTICS/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Nov 24 (Reuters) - Biopharmaceutical company Allos Therapeutics said U.S. regulators have granted orphan drug status for its experimental drug to treat diffuse large b-cell lymphoma (DLBCL), a type of cancer.
Pralatrexate, which has already received FDA's orphan drug status to treat T-cell lymphoma, is being tested as a treatment for large B-cell lymphoma.
DLBCL is a cancer of the B-lymphocytes and represents 30 percent of non-Hodgkin's lymphomas in adults. There are 63,000 new cases in the United States diagnosed per year.
Orphan drug status is given to drugs that treat diseases affecting fewer than 200,000 people in the United States and grants drug developers seven years of market exclusivity.
Shares of the company closed at $6.50 Monday on Nasdaq.
(Reporting by Vidya L Nathan and Anand Basu in Bangalore; Editing by Jarshad Kakkrakandy) Keywords: ALLOSTHERAPEUTICS/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.